However, when co-incubated with PD-L1+ tumor cells, PD-1+ TILs showed a 3–10-fold reduction in ImmTAC®-mediated killing, which was reversed by the addition of anti-PD1 antibody (Fig. 6b and c). This evidence concerns the gene PDCD1 and neoplasm.